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Intermediate-risk cytogenetic acute myeloid leukemia with an internaltandem duplication of FLT3 (FLT3-ITD) is associated with a high riskof relapse, and is now a standard indication for allogeneic stem cell
transplantation. Nevertheless, most studies supporting this strategy have
been performed in young patients. To address the benefit of allogeneic
transplantation in the elderly, we made a selection from the European
Society for Blood and Marrow Transplantation registry of de novo inter-
mediate-risk cytogenetic acute myeloid leukemia harboring FLT3-ITD in
patients aged 60 or over and transplanted from a related or unrelated
donor between January 2000 and December 2015. Two hundred and
ninety-one patients were identified. Most patients received a reduced-
intensity conditioning (82%), while donors consisted of an unrelated
donor in 161 (55%) patients. Two hundred and twelve patients received
their transplantation in first remission, 37 in second remission and 42 in
a more advanced stage of the disease. The 2-year leukemia-free survival
rate was 56% in patients in first remission, 22% in those in second
remission and 10% in patients with active disease, respectively
(P<0.005). Non-relapse mortality for the entire cohort was 20%.   In mul-
tivariate analysis, disease status at transplantation was the most power-
ful predictor of worse leukemia-free survival, graft-versus-host disease
and relapse-free survival, and overall survival. In this elderly population,
age was not associated with outcome. Based on the current results, allo-
geneic transplantation translates into a favorable outcome in fit patients
≥ 60 with FLT3-ITD acute myeloid leukemia in first remission, similarly
to current treatment recommendations for younger patients. 
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ABSTRACT
Introduction
Internal tandem duplication in the juxtamembrane domain of the tyrosine kinase
receptor gene FLT3 (FLT3-ITD) is one of the most frequent recurrent mutations in
acute myeloid leukemia (AML),1-3 and translates into early relapse and worse sur-
vival in young and older AML patients with normal kary-
otype or other intermediate-risk cytogenetics (IRC).4-6
Allogeneic stem cell transplantation (SCT), which has
been shown to be beneficial in first remission (CR1) in
most studies,3,7-11 has emerged as the best consolidation
strategy in these patients. However, the vast majority of
these studies were performed in patients under 60 years of
age, transplanted with a myeloablative conditioning and
using a matched sibling donor, while data for SCT in
patients over 60 years of age harboring FLT3-ITD AML in
CR1, especially with a reduced-intensity conditioning
(RIC) regimen, are rather limited.
The benefit of RIC SCT in AML patients with FLT3-ITD
in CR1 has been observed in a previously reported small-
scale single center study.12 Howbeit, the median age in this
study was 55, ranging from 19 to 64 years, which may not
represent a true elderly population. In a subsequent retro-
spective European Society for Blood and Marrow
Translation (EBMT) study by Schmid et al., the authors
confirmed the significant negative impact of FLT3-ITD on
outcome.13 Moreover, in this cohort, which included
patients of up to 71 years old, advanced age was found to
be a significant negative factor, associated with worse
leukemia-free survival (LFS) and increased non-relapse
mortality (NRM).3,13 Nevertheless, the improvement in
supportive care, human leukocyte antigen (HLA) typing
and the development of new RIC regimens substantially
reduce NRM, extend the eligibility criteria for SCT, and
signify that age should no longer be a barrier to SCT.14,15
Albeit, relapse remains the major cause of treatment fail-
ure with RIC regimens.16,17 Due to the early relapse inci-
dence (RI) in FLT3-ITD AML4 and the intrinsic chemore-
sistance and poor tolerance to therapy in elderly patients,18
the role of SCT in this older population may appear ques-
tionable. To evaluate the potential benefit of SCT in elder-
ly patients with FLT3-ITD AML, we decided to conduct a
retrospective study based on the EBMT registry in order to
address the outcomes of FLT3-ITD AML in patients aged
60 or over and undergoing SCT.
Methods
Patient selection and data collection 
Herein is a retrospective study performed by the Acute
Leukemia Working Party (ALWP) of the EBMT group. The EBMT
registry is a voluntary working group of more than 500 transplant
centers, the participants of which are required to report all consec-
utive SCT and follow-up from their respective centers once a year.
Patients aged 60 or over with a diagnosis of de novo AML trans-
planted between 1st January 2000 and 31st December 2015 with a
related or unrelated donor (10/10 or 9/10) who were reported to
the EBMT registry were included in this analysis. We selected only
those patients with normal karyotype or other intermediate-risk
karyotype. according to the European LeukemiaNet (ELN) classifi-
cation,19,20 and harboring a FLT3-ITD mutation at the time of diag-
nosis. Patients with second SCT have been excluded, as have
those who underwent a cord blood or haploidentical transplanta-
tion. All patients provided informed consent for the use of their
data in retrospective studies. The Review Board of the ALWP as
well as the ethic committee of the EBMT approved this study. A
total of 291 patients from 100 centers met the criteria and were
selected for further analysis.
Myeloablative conditioning (MAC), RIC and non-myeloabla-
tive conditioning regimen (NMA) have been defined elsewhere.21
The following variables were selected and included in the analysis:
year of transplantation, age, sex, white blood cell count (WBC) at
diagnosis, status at transplantation, time from diagnosis to CR,
time from CR to SCT, the number of induction courses to reach
CR, type of conditioning regimen, in vivo T-cell depletion (includ-
ing both anti-thymocyte globulins and alemtuzumab),
cytomegalovirus (CMV) status of donor and recipient, donor type,
source of stem cells, Karnofsky performance status (KPS) at trans-
plantation, engraftment, presence of acute and chronic 
graft-versus-host disease (GvHD), grade of acute GvHD, and
NPM1 status. The molecular remission status at the time of SCT
is center-dependent and was not defined in the registry.
Statistical analysis and endpoints definitions
Endpoints included LFS, RI, NRM, overall survival (OS), acute
and chronic GvHD, and GvHD-free/relapse-free survival (GRFS).
All outcomes were measured from the time of transplant. LFS was
defined as survival without relapse; patients alive without relapse
were censored at the time of last contact. OS was based on death
from any cause. NRM was defined as death without previous
relapse. GRFS was defined as survival without grade 3-4 acute
GvHD, extensive chronic GvHD, relapse or death. Surviving
patients were censored at the time of last contact. The probabili-
ties of OS, LFS and GRFS were calculated by the Kaplan-Meier
test, and those of acute and chronic GvHD, NRM, and relapse
were determined by the cumulative incidence estimator to accom-
modate competing risks. Results are expressed with a 95% confi-
dence interval (CI). For NRM, relapse was the competing risk,
while for relapse the competing risk was NRM. For acute and
chronic GvHD, death without the event and relapse were the
competing risks. 
For all prognostic analyses, continuous variables were catego-
rized and the median was used as a cut-off point, excepting that
of age which was analyzed as a continuous variable in multivari-
ate analysis. A Cox proportional hazards model was used for mul-
tivariate regression. Factors associated with a P-value less than
0.15 by univariate analysis, and other clinically meaningful vari-
ables were included in the model. Results were expressed as the
hazard ratio (HR) with 95% CI. 
All tests were two-sided. The type-1 error rate was fixed at 0.05
for the determination of factors associated with time-to-event out-
comes. Statistical analyses were performed with SPSS 19 (SPSS
Inc./IBM, Armonk, NY, USA) and R 3.0.1 (R Development Core
Team, Vienna, Austria) software packages.
Results
Patients’ characteristics
Characteristics of the 291 selected patients are listed in
Table 1. Median age at SCT was 63.7 years (range: 60-
75.4). Only 12 patients were over 70 years old. The most
frequent RIC was fludarabine and busulfan (N=118), fol-
lowed by fludarabine and melphalan (N=42). Twenty-
three patients, including 15 with active disease, one in sec-
ond complete remission (CR2) and seven in CR1, received
a fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC
preparative regimen.22 In vivo T-cell depletion (TCD)
included 162 patients with anti-thymocyte globulins and
35 patients with alemtuzumab. At the time of SCT, most
patients (252, 94%) had a KPS of more than 80%, and
71% had more than 90%. The characteristics of CR1
patients are summarized in Table 2. Molecular status at
the time of SCT was available for 104 out of 202 CR1
patients; 80 (77%) were in molecular CR1.
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Engraftment and graft-versus-host disease
Engraftment was successful in 268 patients (98%) with
a median time to neutrophils engraftment of 17 days
(range: 6-64). The cumulative incidence of grade II-IV
acute GvHD was 22% (95% CI: 17.7-27.6) and the 2-year
cumulative incidence of chronic GvHD was 34% (95%
CI: 28.4-40.5) (Figure 1). The cumulative incidence of
grade III-IV acute GvHD was 8% (95% CI: 5-12) and the
2-year cumulative incidence of extensive chronic GvHD
was 15% (95% CI: 10.5-19.8). 
In the multivariate analysis performed in the entire pop-
ulation, a lower performance status was associated with
more grade III-IV acute GvHD (16% [95% CI: 8.2-25.2] vs.
6% [95% CI: 3.2-6.2], for patients with KPS of <90% vs.
≥90%, respectively, HR=0.4, 95% CI: 0.17-0.93, P=0.03).
The age of both the patient and donor, type of donor,
source of stem cells, TCD and conditioning intensity were
X. Poiré et al.
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Table 1. Patient characteristics of the entire cohort.  
Patient’s characteristics 
N=291
Median age at SCT (range) 63.7 years old (60-75.4)
Median follow-up (range) 23 months (2-173)
WBC at diagnosis (range) 44.0 x 109/L (1-575)
Median year of SCT 2012 (2002-2015)
Remission status at SCT, N(%)
CR1 212 (72.9%)
CR2 37 (12.7%)
Not in CR 42 (14.4%)
Sex, N(%)
Male 150 (51.5%)
Female 141 (48.5%)
Donor type, N(%)
Sibling 130 (44.7%)
Unrelated 161 (55.3%)
Cytogenetics, N(%)
Normal 254 (87.3%)
Abnormal 37 (12.7%)
NPM1 status, N(%)
Unmutated 50 (24.6%)
Mutated 153 (75.4%)
Missing 88
Source of SC
BM 27 (9.3%)
PB 264 (90.7%)
In vivo T-cell depletion, N(%) 197 (68.4%)
Conditioning regimen, N(%)
MAC 52 (17.9%)
RIC 200 (68.7%)
NMA 39 (13.4%)
Karnofsky > 80%, N(%) 252 (94%)
CMV patient+, N(%) 199 (69%)
CMV donor+, N(%) 153 (53.3%)
Co-morbidity score (HCT-CI)
0 65 (58%)
1-2 22 (19.6%)
3+ 25 (22.3%)
Missing 179
N: number; SCT: stem cell transplantation; WBC: white blood cell count; CR: complete
remission; SC: stem cell; BM: bone marrow; PB: peripheral blood; MAC: myeloablative
conditioning; RIC: reduced-intensity conditioning; NMA: non myeloablative condition-
ing; CMV:  cytomegalovirus; HCT-CI: hematopoietic cell transplant co-morbidity index. 
Table 2. CR1 patients’ characteristics.
Patient’s characteristics 
N=212
Median age at SCT (range) 63.5 years old (60-72.4)
WBC at diagnosis (range) 42.3 x 109/L (1-380)
Median year of SCT 2012 (2002-2015)
Interval from diagnosis to CR1 (range) 42 days (13-149)
Interval from CR1 to SCT (range) 98 days (15-300)
Interval from diagnosis to SCT (range) 5 months (2-17)
Number of induction courses to CR1, N(%)
1 126 (73.7%)
2 or more 45 (26.3%)
Missing 41
Sex , N(%)
Male 110 (51.9%)
Female 102 (48.1%)
Female to male, N(%) 41 (19.3%)
Donor type, N(%)
Sibling 103 (48.6%)
Unrelated 109 (51.4%)
Cytogenetics, N(%)
Normal 183 (86.3%)
Abnormal 29 (13.7%)
NPM1 status, N(%)
Unmutated 35 (23.5%)
Mutated 114 (76.5%)
Missing 63
Molecular CR at SCT
No molecular CR 24 (23.1%)
Molecular CR 80 (76.9%)
Missing 108
Source of SC
BM 23 (10.9%)
PB 189 (89.2%)
In vivo T-cell depletion, N(%) 142 (67.6%)
Conditioning regimen, N(%)
MAC 33 (15.6%)
RIC 146 (68.9%)
NMA 33 (15.6%)
Karnofsky > 80%, N(%) 186 (96.4%)
CMV patient+, N(%) 140 (66.4%)
CMV donor+, N(%) 114 (54.3%)
Co-morbidity score (HCT-CI)
0 47 (57.3%)
1-2 18 (22%)
3+ 17 (20.7%)
Missing 130
N: number; SCT: stem cell transplantation; WBC: white blood cell count; CR1: first com-
plete remission; SC: stem cell; BM: bone marrow; PB: peripheral blood; MAC: myeloab-
lative conditioning; RIC: reduced-intensity conditioning; NMA: non myeloablative
conditioning; CMV: cytomegalovirus; HCT-CI: hematopoietic cell transplant co-mor-
bidity index.  
not significantly associated with the incidence of acute
GvHD. Focusing on the 212 patients transplanted in CR1,
only a better KPS (>90%) at SCT correlated with less
grade II-IV and grade III-IV acute GvHD (HR=0.43, 95%
CI: 0.22-0.82, P=0.01 and HR=0.13, 95% CI: 0.04-0.41,
P=0.0005, respectively).
Regarding chronic GvHD, no correlation was observed
between the cumulative incidence of chronic GvHD and
age, type of donor or source of stem cells. In the multivari-
ate analysis performed in the entire population, better KPS
was associated with more overall chronic GvHD
(HR=1.95, 95% CI: 1.08-3.51, P=0.03), while TCD corre-
lated with less overall chronic GvHD (HR=0.51, 95% CI:
0.32-0.83, P=0.006) and less extensive chronic GvHD
(HR=0.29, 95% CI: 0.14-0.59, P<0.001). We also found
significantly less extensive chronic GvHD with RIC
(P=0.02), and more extensive chronic GvHD with a female
donor to a male recipient (P=0.02). Among patients trans-
planted in CR1, we found a significant impact of donor’s
age, with a higher incidence of chronic GvHD when an
older donor was used (46% [95% CI: 35-56.9] vs. 31%
[95% CI: 21.5-41.7] with a donor aged  >47 and ≤47 years
old, respectively, P=0.04). 
Non-relapse mortality
The 2-year cumulative incidence of NRM for the whole
cohort was 20% (95% CI: 15.6-25.4). In multivariate
analysis, active disease at the time of SCT was significant-
ly associated with increased NRM (P=0.01), while unrelat-
ed donors showed a trend toward a higher NRM (Table 3,
Figure 2A). Thus, 2-year NRM was 18% (95% CI: 12.8-
23.9) in CR1 patients and 29% (95% CI: 15.6-43) in
patients with active disease who underwent transplanta-
tion (HR=2.38, 95%CI: 1.17-4.84, P=0.02). The presence
of chronic GvHD was significantly associated with more
NRM in multivariate analysis (HR=2.38, 95% CI: 1.04-
5.49, P=0.04). In patients transplanted in CR1, the interval
from CR1 to SCT was significantly associated with NRM
in univariate analysis, being 7% (95% CI: 2.9-14.3) for
patients transplanted within 98 days from CR1 and 24%
(95% CI: 15.2-33.5) for patients transplanted more than 98
days from CR1. In multivariate analysis, a 9/10 unrelated
donor was significantly associated with more NRM com-
pared to a sibling donor, whereas NRM from a 10/10 unre-
lated donor SCT was comparable to a sibling donor
(P=0.03 and P=0.42, respectively). Thus, 2-year NRM was
32% (95% CI: 12-53.8) when the SCT was performed
with a 9/10 unrelated donor, 17% (95% CI: 9.7-25.3)
when a sibling donor was used, and 16% (95% CI: 9.2-
25.6) when the donor was a 10/10 unrelated donor. A
longer interval from CR1 to SCT remained significantly
associated with higher NRM in multivariate analysis
(P=0.04) (Table 4). 
Relapse incidence
The 2-year cumulative RI in the overall series was
35.4% (95% CI: 29.6-41.3). RI strongly correlated with
disease status at the time of SCT, at 26.1% (95% CI: 19.9-
32.6), 56.8% (95% CI: 37.1-72.3) and 61.9% (95% CI:
44.9-77) for patients transplanted in CR1, CR2 and not in
remission at the time of SCT, respectively (P<0.001)
(Figure 2B). In multivariate analysis, both CR2 and active
disease were significantly associated with increased RI
compared to patients transplanted in CR1 (P<0.001 and
P<0.001, respectively) (Table 3). The presence of chronic
GvHD was not associated with less relapse (HR=0.96,
95% CI: 0.48-19, P=0.9). Focusing on patients transplant-
ed in CR1, a significant correlation between RI and the
interval from diagnosis to CR1 (P=0.003) was demonstrat-
ed in univariate analysis, in line with the significant asso-
ciation between relapse and the number of induction
courses to achieve CR1 (P<0.001). Thus, RI was 17.5%
(95% CI: 10-26.9) when the interval from diagnosis to
CR1 was less than 42 days, and 34.4% (95% CI: 24.1-44.9)
when this interval was greater than 42 days; this differ-
ence was confirmed in multivariate analysis (HR: 2.32,
95% CI: 1.15-4.7, P=0.02). Being in molecular remission at
the time of SCT was also significantly associated with less
relapse in CR1 patients (17% vs. 44%, P=0.001). Five out
of 24 patients with persistent molecular disease at the
time of SCT received donor lymphocyte infusion (DLI)
compared to 11 out of 80 patients with molecular remis-
sion (P=0.4). Increasing age (as a continuous variable),
NPM1 status, type of donor, and conditioning intensity
did not influence RI in multivariate analysis. TCD showed
a trend toward less relapse in multivariate analysis
(HR=0.53, 95% CI: 0.27-1.04, P=0.06). Molecular status at
the time of SCT was not included in the multivariate
analysis due to an excess of missing data (N=108).
Overall survival, leukemia-free survival and 
graft-versus-host/relapse-free survival
Among the 291 patients, the 2-year probability of OS
was 46.7% (95% CI: 40.4-53.1). Disease status at SCT
was the most powerful factor influencing survival, with a
2-year OS of 58.7% (95% CI: 51.2-66.1) in patients trans-
planted in CR1, 28.8% (95% CI: 12.3-45.4) in those trans-
planted in CR2, and only 9.5% (95% CI: 0.6-18.4) when
transplantation was performed in active disease (P<0.001)
(Figure 2C). In multivariate analysis, only disease status at
the time of SCT (CR2 and active disease compared to
CR1) was significantly associated with decreased OS
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Figure 1. Cumulative incidence of chronic graft-versus-host disease (GvHD).
The 2-year cumulative incidence of chronic GvHD was 34% (95% CI: 28.4-40.5)
in the entire cohort (N=291). 
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(P<0.001; Table 3). Chronic GvHD was not associated
with OS (HR=1.14, 95% CI: 0.74-1.79, P=0.57). In the
cohort of CR1 patients, the 2-year probability of OS was
69.1% (95% CI: 58.9-79.4) in patients with an interval
from diagnosis to CR1 of less than 42 days, and 54.9%
(95% CI: 43.5-66.2) in patients with a longer interval to
diagnosis of CR1 (P=0.06). We also found that a donor age
of more than 47 years old was significantly associated
with improved OS (P=0.02), however, donor’s age was
associated with donor type, being significantly older in
HLA-identical siblings compared with unrelated donors
(53 vs. 36 years old, P<0.001). When we compared the old-
est sibling donors to the youngest unrelated donors
according to median age in each group, we consistently
found better OS with sibling donors, which confirms the
stronger impact of donor type over donor’s age. In multi-
variate analysis adjusted for patients’ age, performance
status, conditioning intensity, donor CMV status and 
in vivo TCD, older sibling donors were still associated with
better OS (HR=0.38, P=0.008) compared to younger unre-
lated donors. Time from CR1 to SCT was significantly
longer for the youngest unrelated donors (107 days, range:
9-198) compared to the oldest sibling donors (83 days,
range: 13-186, P=0.04). The 2-year probability of OS was
62.7% (95% CI: 52.2-73.2) after SCT from a sibling donor,
57.7% (95% CI: 46.3-69.1) after SCT from a 10/10 unre-
lated donor and 42.2% (95% CI: 17.4-67) after SCT from
a 9/10 unrelated donor, respectively, but those differences
did not reach statistical significance across groups
(P=0.27). Age (> or < 65 years old), NPM1 status, molecu-
lar status at SCT, KPS, conditioning intensity, donor CMV
positivity, and TCD were not correlated with OS in uni-
variate analysis. In multivariate analysis, increasing
patient’s age as a continuous variable was significantly
associated with better OS (HR=0.89, 95% CI: 0.8-0.99,
P=0.03), and SCT from 9/10 unrelated donors compared
X. Poiré et al.
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Figure 2. Non-relapse mortality (NRM), relapse incidence (RI), overall survival (OS) and leukemia-free survival (LFS) per disease status (first complete remission
(CR1), second remission (CR2) and active disease (Active D)). (A) The 2-year cumulative incidence of NRM was 18% (95% CI: 12.8-23.9) in CR1 patients, 21.6%
(95% CI: 8.9-37.9) in CR2 patients and 28.6% (95% CI: 15.6-43) in Active D patients. (B) The 2-year cumulative incidence of relapse was 26.1% (95% CI: 19.9-32.6)
in CR1 patients, 56.8% (95% CI: 37.1-72.3) in CR2 patients and 61.9% (95% CI: 44.9-75) in Active D patients. (C) The 2-year probability of OS was 58.7% (95% CI:
51.2-66.1) in CR1 patients, 28.8% (95% CI: 12.3-45.4) and 9.5% (95% CI: 0.6-18.4) in Active D patients. (D) The 2-year probability of LFS was 55.9% (95% CI: 48.6-
63.3) in CR1 patients, 21.6% (95% CI: 6.4-36.8) and 9.5% (95% CI: 0.6-18.4).  
A B
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to sibling donors showed a trend toward worse OS
(P=0.09) (Table 4).
The 2-year probability of LFS was 44.3% (95% CI: 38.1-
50.5) for the whole patient cohort. Disease status had the
strongest impact on LFS, with a 2-year LFS of 55.9% (95%
CI: 48.6-63.3) in patients transplanted in CR1, 21.6%
(95% CI: 6.4-36.8) if transplanted in CR2 and 9.5% (95%
CI: 0.6-18.4) in patients not in CR at the time of SCT
(P<0.001) (Figure 2D). In multivariate analysis, the signifi-
cant influence of disease status at SCT was confirmed
(P<0.001), and donor CMV positivity was also significant-
ly associated with worse LFS (P=0.04) (Table 3). Chronic
GvHD did not correlate with LFS (HR=1.51, 95% CI: 0.92-
2.48, P=0.1). In the cohort of patients transplanted in CR1,
an interval from diagnosis to CR1 of less than 42 days was
significantly associated with better LFS (64.6% vs. 52.5%,
P=0.03). On the contrary, other variables such as age (> or
< 65 years old), NPM1 status, TCD, donor CMV positivity
or conditioning intensity did not show a prognostic
impact on LFS. Similarly to OS, we observed a better LFS
in SCT from donors aged over 47 years old in univariate
(P=0.02) and multivariate analysis (P=0.01). The 2-year
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Table 3. Multivariate analysis using a Cox proportional hazards model, N=291. Shown are variables with P<0.15 in univariate analysis. Non-
relapse mortality, relapse incidence, overall survival and leukemia-free survival.
P HR 95% CI
NRM Age (per year) 0.57 0.97 0.89 1.07
Status at SCT (CR1 as reference)
CR2 0.36 1.55 0.61 3.90
Advanced 0.02 2.38 1.17 4.84
Type of donor (MSD as reference)
10/10 UD 0.06 1.85 0.97 3.52
9/10 UD 0.11 2.02 0.85 4.82
Karnoksky > 90% 0,15 0.66 0.37 1.16
RIC 0.39 0.75 0.38 1.47
Donor CMV+ 0.07 1.76 0.95 3.26
In vivo TCD 0.90 1.04 0.56 1.92
RI Age (per year) 0.23 0.96 0.89 1.03
Status at SCT (CR1 as reference)
CR2 0.00001 4.59 2.37 8.87
Advanced <0.00001 4.23 2.42 7.39
Type of donor (MSD as reference)
10/10 UD 0.81 0.94 0.56 1.57
9/10 UD 0.68 0.86 0.41 1.78
Karnoksky > 90% 0.72 1.10 0.67 1.79
RIC 0.63 1.16 0.64 2.08
Donor CMV+ 0.21 1.37 0.84 2.25
In vivo TCD 0.15 0.71 0.44 1.13
OS Age (per year) 0.31 0.97 0.91 1.02
Status at SCT (CR1 as reference)
CR2 0.0004 2.64 1.53 4.55
Advanced <0.00001 3.35 2.13 5.26
Type of donor (MSD as reference)
10/10 UD 0.17 1.34 0.88 2.03
9/10 UD 0.26 1.40 0.79 2.48
Karnoksky > 90% 0.41 0.85 0.58 1.25
RIC 0.53 1.16 0.72 1.87
Donor CMV+ 0.06 1.47 0.99 2.19
In vivo TCD 0.43 0.85 0.58 1.26
LFS Age (per year) 0.19 0.96 0.91 1.02
Status at SCT (CR1 as reference)
CR2 0.00004 3.04 1.79 5.16
Advanced <0.00001 3.30 2.13 5.11
Type of donor (MSD as reference)
10/10 UD 0.31 1.23 0.83 1.83
9/10 UD 0.51 1.21 0.69 2.11
Karnoksky > 90% 0.51 0.89 0.61 1.28
RIC 0.87 0.97 0.62 1.50
Donor CMV+ 0.04 1.51 1.03 2.23
In vivo TCD 0.28 0.82 0.56 1.18
N: number; NRM: non-relapse mortality; RI: relapse incidence; OS: overall survival; LFS: leukemia-free survival; HR: hazard ratio; CI: confidence interval; SCT: stem cell transplan-
tation; CR1: first complete remission; CR2: second remission; UD: unrelated donor; MSD: matched sibling donor; CMV: cytomegalovirus; TCD: T-cell depletion; RIC: reduced-inten-
sity conditioning.  
probability of LFS was 62.7% (95% CI: 52.2-73.2) after
SCT from a sibling donor, 57.7% (95% CI: 46.3-69.1) after
SCT from a 10/10 unrelated donor, and 42.2% (95% CI:
17.4-67) after SCT from a 9/10 unrelated donor, respec-
tively, however, as with OS, those differences did not
reach significance (P=0.27). In multivariate analysis,
increasing patient’s age as a continuous variable and a
shorter interval from diagnosis to CR1 were both signifi-
cantly associated with better LFS (P=0.03 and P=0.05,
respectively) (Table 4).
The 2-year probability of GRFS was 32.3% (95% CI:
26.3-38.3) in the study population. A worse GRFS was
seen with more advanced disease; 41.7% (95% CI: 34.3-
49.2) in patients transplanted in CR1, 18.1% (95% CI: 3.6-
32.6) and 2.4% (95% CI: 0-7.2) in patients with CR2 and
active disease at the time of SCT, respectively (P<0.001)
(Figure 3). Multivariate analysis performed on GRFS with-
in the entire cohort and the CR1 patients is available in the
Online Supplementary Material.
We also focused on the two main conditioning regimens
within CR1 patients, which were fludarabine and busul-
fan (N=95), followed by fludarabine and melphalan
(N=30). We found no significant differences in terms of
acute and chronic GvHD incidence, NRM, RI, OS and LFS
between those two regimens in univariate analysis (data
not shown).
Discussion
SCT is becoming a routine standard of care consolida-
tion strategy for younger patients with AML and FLT3-
ITD.3,8-11,23 Nonetheless, its potential benefit for older
patients has not been specifically addressed, and there is
currently no strong evidence which supports SCT for eld-
erly patients with FLT3-ITD AML.13,24 Against this back-
ground, our study demonstrated that in patients with an
age equal to or over 60 years old, SCT performed in CR1
translates into a 2-year OS and LFS of 59% and 56%,
respectively. A NRM and RI rate of 18% and 25%, respec-
tively, are acceptable in this population. Interestingly,
these results are only slightly inferior than those reported
in younger patients, and suggest the relevance of graft-ver-
sus-leukemia (GvL) for disease control in this entity.8,13,24
Moreover, increasing age was not associated with NRM
and other outcomes within our population, probably
reflecting a careful and adequate selection process in the
elderly AML population submitted to SCT in CR1. On the
contrary, we found very poor outcomes when SCT was
performed beyond CR1, thus, the benefit of SCT in these
situations remains questionable. The inferior results
obtained in CR2 patients are in accordance with previous
publications.25,26 Based on our sizable dataset, we strongly
recommend that SCT is offered as the best consolidation
strategy for eligible patients in early disease phase with
AML and FLT3-ITD.27-29 
It is possible that we have to concede a selection bias in
our study, howbeit this bias supports the need for a thor-
ough evaluation of each older candidate prior to SCT. We
did not find any difference in characteristics between the
youngest and oldest patients from our population, such as
time from diagnosis to CR1, conditioning regimen,
hematopoietic cell transplant co-morbidity index (HCT-
CI) or KPS. The superior OS and LFS observed among the
oldest patients of our study may be explained by individ-
ual characteristics not reported in the registry. KPS and
HCT-CI are well-described tools used to evaluate patients
before SCT, and are reliable even in older patients.15,17 In
addition to HCT-CI, other tools have been described in
the assessment of elderly patients undergoing anti-
leukemic therapy, and found that chronologic age is defin-
itively not a limiting factor.16,30-32 This assessment included
the functional, cognitive, biological, nutritional and med-
ical evaluation of each patient, and helped us to discern
the best candidate for intensive therapy or SCT.33,34 
NPM1mutation had no impact on any outcome param-
eter in this study. The favorable prognostic influence of
NPM1 has been demonstrated in patients of up to 65 years
of age, although it is less pronounced or even lost in older
subjects.35,36 Several studies focused on younger patients
have shown that NPM1 mutation may influence OS and
LFS in FLT3-ITD AML,37-39 however, this impact is
observed primarily in patients with a low allelic ratio of
FLT3-ITD.37,39,40 In NPM1-mutated AML, only patients har-
boring a high level of FLT3-ITD may benefit unequivocal-
ly from SCT.41-44 Information regarding the FLT3-ITD allel-
ic burden was not available in our study, and, given the
lack of current standardization, it remains extremely diffi-
cult to analyze it in a multicenter registry setting.45
Moreover, the concurrent mutation of DNMT3A, fre-
quently found in combination with FLT3-ITD and NPM1
mutation, may have a profound adverse prognostic
impact, and the capacity for SCT to overcome this poor
prognosis is currently unknown.2,46-48 We also found that
patients transplanted in molecular remission at the time of
SCT had a better outcome after SCT, with a decreased
relapse risk and a trend toward improved LFS and GRFS,
a fact which has been recently addressed by Gaballa et al.49
Nonetheless, the role of upfront SCT for patients who fail
to achieve a molecular remission before SCT is unknown,
and the benefit of donor lymphocyte infusion or other
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Figure 3. Graft-versus-host disease and relapse-free survival (GRFS) per dis-
ease status (first complete remission (CR1), second remission (CR2) and active
disease (Active D)). The 2-year probability of GRFS was 41.7% (95% CI: 34.3-
49.2) in CR1 patients, 18.1% (95% CI: 3.6-32.6) in CR2 patients and 2.4% (95%
CI: 0-7.2) in Active D patients.
maintenance therapy in this setting should be specifically
addressed in future studies.
A relevant issue concerning FLT3-ITD AML is the
potential benefit of the use of FLT3 inhibitors in combina-
tion with intensive chemotherapy in patients undergoing
SCT. In this regard, the addition of midostaurin to
chemotherapy in newly diagnosed FLT3-ITD AML has
been showed to significantly improve survival, even in
patients undergoing SCT in CR1, suggesting that a deeper
anti-leukemic response before SCT can translate into an
improved outcome after transplant.50 Since information on
the use of FLT3 inhibitors pre- and post-transplant was not
available in this registry study, we were unable to specifi-
cally analyze their effects. The prevention of relapse after
SCT8,13 with post-transplant maintenance therapy based
on FLT3 inhibitors is an area of current preferential inter-
est, and is being investigated via ongoing clinical trials
using agents such as sorafenib, midostaurin or gilteritinib.
Small retrospective studies on maintenance with sorafenib
have resulted in reduced RI and improved survival with-
out increased toxicity.51-54 Nevertheless, SCT remains the
best consolidation therapy offered to date, and the use of
FLT3 inhibitors may only increase the proportion of
patients, including frailer subjects, who might benefit
from SCT. 
Herein, transplantation from 9/10 unrelated donors was
associated with significant higher NRM and a trend
toward inferior OS and LFS compared to sibling donors
and 10/10 unrelated donors, as previously reported.55,56
However, an unrelated donor may be preferable due to
the fact that older patients have older sibling donors, and
donor age has been associated with decreased survival due
to an excess of acute and chronic GvHD.57 Of note,
improved survival has been observed with the use of
younger unrelated donors compared to older sibling
donors in an EBMT retrospective study,58 while another
large study from the Center for International Blood and
Marrow Transplant Research (CIBMTR) reported no dif-
ference in terms of outcomes between younger matched
unrelated donors and older sibling donors.59 Among our
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Table 4. Multivariate analysis using a Cox proportional hazards model, N=212 (CR1 patients). Shown are variables with P<0.15 in univariate
analysis. Non-relapse mortality, relapse incidence, overall survival and leukemia-free survival.
P HR 95% CI
NRM Age (per year) 0.15 0.88 0.75 1.05
Type of donor (MSD as reference)
10/10 UD 0.42 1.46 0.58 3.68
9/10 UD 0.03 3.58 1.15 11.13
Kanofsky > 90% 0.10 0.52 0.23 1.14
RIC 0.28 0.56 0.20 1.61
Diagnosis to CR1 > 42 days 0.61 1.23 0.56 2.68
CR1 to SCT > 98 days 0.04 2.50 1.06 5.91
In vivo TCD 0.75 1.15 0.50 2.66
RI Age (per year) 0.10 0.90 0.79 1.02
Type of donor (MSD as reference)
10/10 UD 0.41 1.36 0.65 2.87
9/10 UD 0.71 0.76 0.17 3.41
Kanofsky > 90% 0.37 1.45 0.64 3.25
RIC 0.77 1.18 0.40 3.48
Diagnosis to CR1 > 42 days 0.02 2.32 1.15 4.70
CR1 to SCT > 98 days 0.21 0.63 0.31 1.28
In vivo TCD 0.06 0.53 0.27 1.04
OS Age (per year) 0.03 0.89 0.80 0.99
Type of donor (MSD as reference)
10/10 UD 0.29 1.39 0.76 2.54
9/10 UD 0.10 2.14 0.88 5.23
Kanofsky > 90% 0.52 0.83 0.47 1.47
RIC 0.87 0.94 0.43 2.06
Diagnosis to CR1 > 42 days 0.16 1.47 0.86 2.52
CR1 to SCT > 98 days 0.71 1.11 0.64 1.93
In vivo TCD 0.36 0.78 0.45 1.34
LFS Age (per year) 0.03 0.89 0.80 0.99
Type of donor (MSD as reference)
10/10 UD 0.29 1.36 0.77 2.42
9/10 UD 0.13 1.9 0.82 4.40
Kanofsky > 90% 0.73 0.91 0.52 1.57
RIC 0.64 0.84 0.40 1.75
Diagnosis to CR1 > 42 days 0.05 1.67 1.02 2.79
CR1 to SCT > 98 days 0.59 1.15 0.69 1.93
In vivo TCD 0.25 0.74 0.44 1.23
N: number; NRM: non-relapse mortality; RI: relapse incidence; OS: overall survival; LFS: leukemia-free survival; HR: hazard ratio; CI: confidence interval; CR1: first complete remis-
sion; UD: unrelated donor; MSD: matched sibling donor; RIC: reduced-intensity conditioning; TCD: T-cell depletion.
CR1 patients, we found that older donor age (>47 years
old) was associated with more chronic GvHD, but better
OS and LFS, and had no effect on RI. However, the age of
the donor was strongly associated with the type of donor.
The effect of donor type on outcomes was more potent
than that of donor age, and our observations favor the use
of a sibling donor, if eligible for stem cell donation. If a sib-
ling donor is not available, a 10/10 fully matched unrelated
donor is a suitable option, but caution must be applied
with the use of a 9/10 unrelated donor. Nevertheless, we
found a shorter interval from CR1 to SCT with sibling
donors compared to older donors. We suggest an early
donor search in order to further improve the results
obtained with unrelated donors. TCD was significantly
associated with less chronic GvHD and less extensive
chronic GvHD, with no effect on OS and LFS. We did not
find a beneficial effect of chronic GvHD on RI and LFS to
support the existence of a GvL effect in our population.
In conclusion, SCT emerges as a recommended consoli-
dation strategy for fit patients aged 60 or over with AML
and FLT3-ITD in CR1. Based on our study, and in view of
the inferior results observed when SCT is performed in
CR2 and beyond, we do not recommend postponing SCT
until relapse. However, the few patients over 70 years of
age included herein preclude firm recommendations for
older patients. Sibling donors or fully matched unrelated
donors remain the best donor choice in this older popula-
tion.
X. Poiré et al.
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